Michela Falco

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2546782/publications.pdf

Version: 2024-02-01

120	10,560	36303	31849
papers	citations	51 h-index	101 g-index

125	125	125	10070
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	TCRÎ±Î²/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders. Blood Advances, 2022, 6, 281-292.	5.2	22
2	Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia. Cancer Immunology Research, 2022, 10, 291-302.	3.4	17
3	CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma. Frontiers in Immunology, 2022, 13, 837457.	4.8	9
4	Haploidentical Stem Cell Transplantation After TCR-Î±Î²+ and CD19+ Cells Depletion In Children With Congenital Non-Malignant Disease. Transplantation and Cellular Therapy, 2022, 28, 394.e1-394.e9.	1.2	10
5	Characterization of <scp>KIR</scp> ⁺ <scp>NK</scp> cell subsets with a monoclonal antibody selectively recognizing <scp>KIR2DL1</scp> and blocking the specific interaction with <scp>HLAâ€C</scp>. Hla, 2022, , .	0.6	5
6	Epitope characterization of a monoclonal antibody that selectively recognizes <scp>KIR2DL1</scp> allotypes. Hla, 2022, , .	0.6	3
7	Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches. Cancers, 2021, 13, 1577.	3.7	5
8	ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function. Frontiers in Immunology, 2021, 12, 778103.	4.8	6
9	Mitochondria as playmakers of apoptosis, autophagy and senescence. Seminars in Cell and Developmental Biology, 2020, 98, 139-153.	5.0	305
10	Phenotypic and Functional Characterization of NK Cells in Î±Î²T-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia. Cancers, 2020, 12, 2187.	3.7	19
11	Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Frontiers in Immunology, 2019, 10, 1179.	4.8	269
12	NK Cell-Based Immunotherapy for Hematological Malignancies. Journal of Clinical Medicine, 2019, 8, 1702.	2.4	54
13	An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More. Frontiers in Immunology, 2019, 10, 1415.	4.8	57
14	Natural killer cells: From surface receptors to the cure of highâ€risk leukemia (Ceppellini Lecture). Hla, 2019, 93, 185-194.	0.6	11
15	NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia. Trends in Immunology, 2018, 39, 577-590.	6.8	119
16	Analysis of KIR3DP1 Polymorphism Provides Relevant Information on Centromeric KIR Gene Content. Journal of Immunology, 2018, 201, 1460-1467.	0.8	7
17	Late Development of FcÎ¼RÎ³neg Adaptive Natural Killer Cells Upon Human Cytomegalovirus Reactivation in Umbilical Cord Blood Transplantation Recipients. Frontiers in Immunology, 2018, 9, 1050.	4.8	42
18	Alpha/Beta T-Cell and B-Cell Depletion HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is an Effective Treatment for Children/Young Adults with Acute Leukemia. Blood, 2018, 132, 2169-2169.	1.4	1

#	Article	IF	Citations
19	Outcome of children with acute leukemia given HLA-haploidentical HSCT after Î±Î² T-cell and B-cell depletion. Blood, 2017, 130, 677-685.	1.4	261
20	Inhibitory 2B4 contributes to NK cell education and immunological derangements in XLP1 patients. European Journal of Immunology, 2017, 47, 1051-1061.	2.9	15
21	A conserved energetic footprint underpins recognition of human leukocyte antigen-E by two distinct Î±Î² T cell receptors. Journal of Biological Chemistry, 2017, 292, 21149-21158.	3.4	20
22	Anticancer and Anti-Inflammatory Properties of Ganoderma lucidum Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment. Nutrients, 2017, 9, 210.	4.1	91
23	Role of Nigella sativa and Its Constituent Thymoquinone on Chemotherapy-Induced Nephrotoxicity: Evidences from Experimental Animal Studies. Nutrients, 2017, 9, 625.	4.1	32
24	KIR3DS1-Mediated Recognition of HLA-*B51: Modulation of KIR3DS1 Responsiveness by Self HLA-B Allotypes and Effect on NK Cell Licensing. Frontiers in Immunology, 2017, 8, 581.	4.8	24
25	Impact of Donor-Specific anti-HLA antibodies and donor KIR characteristics in haploidentical HSCT for beta-Thalassemia. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017020.	1.3	5
26	The Role of miRNAs in the Regulation of Pancreatic Cancer Stem Cells. Stem Cells International, 2016, 2016, 1-7.	2.5	23
27	Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX. BioMed Research International, 2016, 2016, 1-11.	1.9	43
28	The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells. Stem Cells International, 2016, 2016, 1-10.	2.5	320
29	Hematopoietic stem cell transplantation: Improving alloreactive Bw4 donor selection by genotyping codon 86 of KIR3DL1/S1. European Journal of Immunology, 2016, 46, 1511-1517.	2.9	21
30	Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biology, 2016, 6, 160254.	3.6	21
31	Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition. Journal of Experimental Medicine, 2016, 213, 791-807.	8.5	81
32	Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing ÂÂ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies. Haematologica, 2016, 101, 371-381.	3.5	80
33	Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. Cancer Immunology, Immunotherapy, 2016, 65, 465-476.	4.2	34
34	T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT) Followed By Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies. Blood, 2016, 128, 4683-4683.	1.4	1
35	Electrochemotherapy in pancreatic adenocarcinoma treatment: pre-clinical and clinical studies. Radiology and Oncology, 2016, 50, 14-20.	1.7	19
36	ERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors. Cancer Research, 2015, 75, 824-834.	0.9	52

#	Article	IF	Citations
37	Natural Killer (NK) Alloreactivity Seems Not to Play a Role in Preventing Leukemia Relapse in Unmanipulated Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide. Blood, 2015, 126, 2033-2033.	1.4	1
38	Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors. Frontiers in Immunology, 2014, 5, 87.	4.8	77
39	Human Cytomegalovirus Infection Promotes Rapid Maturation of NK Cells Expressing Activating Killer Igâ€“like Receptor in Patients Transplanted with NKG2Câ^'/â^' Umbilical Cord Blood. Journal of Immunology, 2014, 192, 1471-1479.	0.8	176
40	HLA-haploidentical stem cell transplantation after removal of Î±Î²+ T and B cells in children with nonmalignant disorders. Blood, 2014, 124, 822-826.	1.4	385
41	<scp>XLP</scp>1 inhibitory effect by 2<scp>B</scp>4 does not affect <scp>DNAM</scp>â€1 and <scp>NKG</scp>2<scp>D</scp> activating pathways in <scp>NK</scp> cells. European Journal of Immunology, 2014, 44, 1526-1534.	2.9	20
42	Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis. Journal of Allergy and Clinical Immunology, 2014, 134, 1381-1387.e7.	2.9	14
43	<scp>KIR</scp> and <scp>KIR</scp> ligand polymorphism: a new area for clinical applications?. Tissue Antigens, 2013, 82, 363-373.	1.0	60
44	Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Frontiers in Immunology, 2013, 4, 15.	4.8	98
45	Impact of HCMV Infection on NK Cell Development and Function after HSCT. Frontiers in Immunology, 2013, 4, 458.	4.8	41
46	Removal Of Alpha/Beta+ T Cells and Of CD19+ B Cells From The Graft Translates Into Rapid Engraftment, Absence Of Visceral Graft-Versus-Host Disease and Low Transplant-Related Mortality In Children With Acute Leukemia Given HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 157-157.	1.4	4
47	Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood, 2012, 119, 399-410.	1.4	241
48	Human NK receptors: From the molecules to the therapy of high risk leukemias. FEBS Letters, 2011, 585, 1563-1567.	2.8	36
49	Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood, 2011, 117, 4284-4292.	1.4	104
50	A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood, 2010, 116, 1637-1647.	1.4	83
51	Combined Genotypic and Phenotypic Killer Cell Ig-Like Receptor Analyses Reveal KIR2DL3 Alleles Displaying Unexpected Monoclonal Antibody Reactivity: Identification of the Amino Acid Residues Critical for Staining. Journal of Immunology, 2010, 185, 433-441.	0.8	32
52	GPR56 as a novel marker identifying the CD56dull CD16+ NK cell subset both in blood stream and in inflamed peripheral tissues. International Immunology, 2010, 22, 91-100.	4.0	33
53	Extending killer Ig-like receptor function: from HLA class I recognition to sensors of microbial products. Trends in Immunology, 2010, 31, 289-294.	6.8	24
54	OR.69. Alloreactive NK Cells Exert Anti-leukemia Activity in Haplo-HSCT to Pediatric Patients: Revised Role of Activating and Inhibitory KIR. Clinical Immunology, 2009, 131, S29.	3.2	0

#	Article	IF	Citations
55	Rock-type control on erosion-induced uplift, eastern Swiss Alps. Earth and Planetary Science Letters, 2009, 278, 278-285.	4.4	66
56	Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood, 2009, 113, 3119-3129.	1.4	343
57	Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells. PLoS ONE, 2009, 4, e8132.	2.5	36
58	Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function. European Journal of Immunology, 2008, 38, 2284-2289.	2.9	53
59	Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC. International Immunology, 2008, 20, 1155-1167.	4.0	110
60	Anti-Leukemia Activity of Alloreactive NK Cells in Haploidentical HSCT in Pediatric Patients: Re-Defining the Role of Activating and Inhibitory KIR. Blood, 2008, 112, 3002-3002.	1.4	2
61	CD56brightCD16â˜' Killer Ig-Like Receptorâ˜' NK Cells Display Longer Telomeres and Acquire Features of CD56dim NK Cells upon Activation. Journal of Immunology, 2007, 178, 4947-4955.	0.8	430
62	Heterogeneity of TLR3 mRNA transcripts and responsiveness to poly (I:C) in human NK cells derived from different donors. International Immunology, 2007, 19, 1341-1348.	4.0	26
63	Analysis of natural killer cells isolated from human decidua: evidence that 2B4 (CD244) functions as an inhibitory receptor and blocks NK-cell function. Blood, 2006, 108, 4078-4085.	1.4	117
64	Structural basis for a major histocompatibility complex class Ibâ€"restricted T cell response. Nature Immunology, 2006, 7, 256-264.	14.5	109
65	OR.69. Hla-E-Restricted Cytolytic T Lymphocytes: Their Role in Cytomegalovirus Infection and Transplantation. Clinical Immunology, 2006, 119, S29-S30.	3.2	0
66	Analysis of the receptor-ligand interactions in the natural killerâ€"mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood, 2005, 105, 2066-2073.	1.4	344
67	Identification of effector-memory CMV-specific Tâ€„lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion. European Journal of Immunology, 2005, 35, 3240-3247.	2.9	76
68	Distinctive Lack of CD48 Expression in Subsets of Human Dendritic Cells Tunes NK Cell Activation. Journal of Immunology, 2005, 175, 3690-3697.	0.8	26
69	Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2. International Immunology, 2004, 16, 1459-1466.	4.0	15
70	Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells. European Journal of Immunology, 2004, 34, 1663-1672.	2.9	90
71	CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10116-10121.	7.1	412
72	HLA-Eâ€"restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes. Human Immunology, 2004, 65, 437-445.	2.4	42

#	Article	IF	Citations
73	Human Natural Killer cell receptors: insights into their molecular function and structure. Journal of Cellular and Molecular Medicine, 2003, 7, 376-387.	3.6	102
74	CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity. European Journal of Immunology, 2003, 33, 3367-3376.	2.9	77
75	HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10896-10901.	7.1	175
76	Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood, 2003, 102, 1797-1805.	1.4	106
77	Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4526-4531.	7.1	174
78	Identification of HLA-E-specific alloreactive T lymphocytes: A cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11328-11333.	7.1	87
79	p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells. Immunological Reviews, 2001, 181, 260-268.	6.0	47
80	Identification of NKp80, a novel triggering molecule expressed by human NK cells. European Journal of Immunology, 2001, 31, 233-242.	2.9	185
81	The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR Î±/Î²-mediated recognition. European Journal of Immunology, 2001, 31, 3687-3693.	2.9	91
82	Gntb-A, a Novel Sh2d1a-Associated Surface Molecule Contributing to the Inability of Natural Killer Cells to Kill Epstein-Barr Virusâ€“Infected B Cells in X-Linked Lymphoproliferative Disease. Journal of Experimental Medicine, 2001, 194, 235-246.	8.5	287
83	Identification of NKp80, a novel triggering molecule expressed by human NK cells. European Journal of Immunology, 2001, 31, 233-242.	2.9	15
84	Regulation of myeloid cell proliferation and survival by p75/AIRM1 and CD33 surface receptors. Advances in Experimental Medicine and Biology, 2001, 495, 55-61.	1.6	4
85	X-linked lymphoproliferative disease: the dark side of 2b4 function. Advances in Experimental Medicine and Biology, 2001, 495, 63-67.	1.6	3
86	2B4 functions as a co-receptor in human NK cell activation. European Journal of Immunology, 2000, 30, 787-793.	2.9	202
87	Identification and molecular characterization of a natural mutant of the p50.2/KIR2DS2 activating NK receptor that fails to mediate NK cell triggering. European Journal of Immunology, 2000, 30, 3569-3574.	2.9	15
88	X-Linked Lymphoproliferative Disease. Journal of Experimental Medicine, 2000, 192, 337-346.	8.5	438
89	Human natural killer cell activating receptors. Molecular Immunology, 2000, 37, 1015-1024.	2.2	36
90	Identification and Molecular Cloning of P75/Airm1, a Novel Member of the Sialoadhesin Family That Functions as an Inhibitory Receptor in Human Natural Killer Cells. Journal of Experimental Medicine, 1999, 190, 793-802.	8.5	201

#	Article	IF	Citations
91	Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 15091-15096.	7.1	137
92	Identification of the rat homologue of the human NKp46 triggering receptor. Immunology Letters, 1999, 68, 411-414.	2.5	44
93	p49, A putative HLA-G1-specific inhibitory NK receptor belonging to the Immunoglobulin Superfamily. Journal of Reproductive Immunology, 1999, 43, 157-165.	1.9	22
94	Normal Epithelial Cells Modulating HLA Class I Surface Molecules Are Susceptible to Lysis Mediated by CD3+and CD3â^'â€œNonspecificâ€•Killer Cells. Cellular Immunology, 1998, 190, 183-190.	3.0	3
95	p49, a putative HLA class I-specific inhibitory NK receptor belonging to the immunoglobulin superfamily. European Journal of Immunology, 1998, 28, 1980-1990.	2.9	144
96	Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: Interaction with HLA and T-cell receptor. Hepatology, 1997, 26, 1027-1034.	7.3	57
97	HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex. European Journal of Immunology, 1997, 27, 1875-1880.	2.9	84
98	Molecular Structures of HLA-Specific Human NK Cell Receptors. Chemical Immunology and Allergy, 1996, 64, 88-103.	1.7	4
99	Molecular Structures of HLA-Specific Human NK Cell Receptors. Chemical Immunology and Allergy, 1996, 64, 88-103.	1.7	2
100	A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. European Journal of Immunology, 1996, 26, 1816-1824.	2.9	126
101	The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer.. Journal of Experimental Medicine, 1996, 184, 505-518.	8.5	340
102	The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions.. Journal of Experimental Medicine, 1996, 183, 645-650.	8.5	326
103	Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by "group 2" or "group 1" NK clones.. Journal of Experimental Medicine, 1995, 182, 605-609.	8.5	209
104	DQA1â^—03 subtypes have different associations with DRB1 and DQB1 alleles. Human Immunology, 1994, 39, 290-298.	2.4	19
105	A novel HLA-DRB1 allele (DRB1*0417) in South American Indians. Immunogenetics, 1993, 38, 463-463.	2.4	19
106	HLA-DPB1 alleles in a population from South China. Immunogenetics, 1993, 37, 251-6.	2.4	8
107	Suspension feeding in adult Nephrops norvegicus (L.) and Homarus gammarus (L.) (decapoda). Journal of Sea Research, 1993, 31, 291-297.	1.0	39
108	Allelic distribution of DQA1, DQB1, DRB1 and DPB1 in 13 populations suggest a distinctive evolutionary history for the DPB1 locus. Human Immunology, 1993, 37, 26.	2.4	0

#	Article	IF	Citations
109	Differences in HLA class II alleles of isolated South American Indian populations from Brazil and Argentina. Human Immunology, 1993, 37, 213-220.	2.4	117
110	Allospecific natural killer cells are generated by reciprocal stimulation across a diallelic polymorphism of HLA-C. Human Immunology, 1993, 36, 66.	2.4	0
111	Analysis of HLA-C polymorphism by PCR and SSO. Human Immunology, 1993, 36, 56.	2.4	0
112	HLA-C locus polymorphism analyzed by molecular approach. Human Immunology, 1993, 37, 18.	2.4	0
113	Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science, 1993, 260, 1121-1124.	12.6	223
114	HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 12000-12004.	7.1	419
115	Analysis of HLA DP, DQ, and DR allesles in adult Italian rheumatoid arthritis patients. Human Immunology, 1992, 34, 135-141.	2.4	28
116	Production and characterization of murine monoclonal antibodies recognizing HLA-DQ polymorphisms obtained by immunizing mice with transfected L cells. Human Immunology, 1992, 34, 126-134.	2.4	3
117	DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. Human Immunology, 1992, 33, 163-173.	2.4	81
118	Production of two human hybridomas secreting antibodies to HLA-DRw11 and -DRw8+w12 specificities. Human Immunology, 1991, 31, 86-93.	2.4	16
119	Characterization of two human monoclonal antibodies recognizing HLAâ€A30 and HLAâ€A3+A31, respectively. Tissue Antigens, 1991, 38, 224-227.	1.0	10
120	ANALYSIS OF HLA SPECIFICITY OF HUMAN MONOCLONAL ANTIBODIES BY CYTOFLUORIMETRY AND CELL ELISA. International Journal of Immunogenetics, 1991, 18, 345-353.	1.2	0